Co-FundNI
VC Fund
Belfast, United Kingdom
Co-FundNI is a VC fund in Belfast focused on Software and Health Care. Through Co-Fund NI £12.5million will be made available to invest alongside business angels and business angel syndicates (hereafter referred to as "private investors" or "syndicates") into eligible SME's based in Northern Ireland. When matched 45% public with 55% private investors on a deal-by-deal basis this will give anoverall "fund" size of £28m.This initiative is provided by Invest Northern Ireland and part-financed by the European Regional Development Fund under the Invest for Growth and Jobs Programme 2014-2020.
- Total investments:
- 44
- Last investment:
- Lead investor:
- 18%
Last updated:
For AI agents: llms.txt
Industries Co-FundNI invests in
Stages Co-FundNI invests in
Countries Co-FundNI invests in
Round sizes
Round size
- Seed
- $393k–$1.8M
- Venture - Series Unknown
- $461k–$5.7M
Investment Focus
Industry
- Software 10 (23%)
- Health Care 9 (20%)
- Information Technology 7 (16%)
- Biotechnology 5 (11%)
- Medical 4 (9%)
Stage
- Seed 16 (36%)
- Venture - Series Unknown 12 (27%)
- Funding Round 5 (11%)
- Series A 3 (7%)
- Pre-Seed 2 (5%)
Country
- United Kingdom 35 (80%)
- Ireland 1 (2%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Cumulus Neuroscience
|
Cumulus Neuroscience has created a next-generation integrated physiological and digital biomarker platform. | $4.8M / Venture - Series Unknown / Jul 08, 2025 | |
AMPLY Discovery
|
AMPLY Discovery is to develop new biological molecules for anti-infective health and nutrition applications in animal and human health. | $1.8M / Seed / May 01, 2025 | |
GenoMe Diagnostics
|
GenoMe Diagnostics develops OvaME product that helps in improvement of status quo of CA125 blood tests. | $1.7M / Seed / Mar 03, 2023 | |
Kinsetsu
|
Kinsetsu provides intelligent tracking solutions to help organisations automate and optimise tasks and services. | $1.9M / Venture - Series Unknown / Jan 10, 2023 | |
|
Kinsetsu
|
Kinsetsu provides intelligent tracking solutions to help organisations automate and optimise tasks and services. | $1.9M / Venture - Series Unknown / Jan 10, 2023 | |
Re-Vana Therapeutics
|
Re-Vana Therapeutics is a ocular pharmaceuticals & drug delivery company focused on the development and commercialisation of innovative long-acting, biodegradable drug delivery platforms to address ophthalmic conditions such as age-related macular degeneration (AMD), diabetic retinopathy (DR), glaucoma and ocular infections.Their deliveryplatforms enable tailored delivery of therapeutics for long-term and can be administered by various routes to the eye. By using their platform technologies, delivery of a broad range of molecules including proteins, peptides, and small molecules can be achieved from 1 week to 1 year. The platform technologies are based on FDA-approved polymers.Their injectable platform, OcuLief™, can be tailored for the treatment of AMD and DR to achieve a long-term release of anti-vascular endothelial growth factors (anti-VEGF) or corticosteroids for 1-12 months. Their preformed platform, EyeLief™, can be tailored for the treatment of Glaucoma and retina diseases, to achieve a long-term release of small or large molecules for 6 months or more.The design strategy of Re-Vana revolves around increasing patient compliance by reducing pain and frequency of treatment, lowering side effects by controlled drug release, and cost saving for health care providers and pharmaceutical companies. | $12.1M / Series A / Nov 30, 2022 | |
CV6 Therapeutics
|
CV6 Therapeutics is a drug development company focused on the discovery, development and commercialization of novel therapies for the treatment of human diseases. | $5.7M / Venture - Series Unknown / Nov 02, 2022 | |
|
AMPLY Discovery
|
AMPLY Discovery is to develop new biological molecules for anti-infective health and nutrition applications in animal and human health. | $1M / Seed / Sep 21, 2022 | |
VascVersa
|
VascVersa is a med-tech company specializing in vascular regeneration. | $604.3K / Seed / Aug 08, 2022 | |
Sonrai Analytics
|
Sonrai develop applications and interfaces to utilize the data and the resultant outputs of analysis and combine this with AI and ML to make your data predictive. | $2.6M / Seed / Jun 21, 2022 | |
| See all 44 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Co-FundNI invest in?
Co-FundNI invests primarily in Software, Health Care and Information Technology startups, most often at Seed and Venture - Series Unknown stage. Most of the 44 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Co-FundNI's check size?
Co-FundNI typically joins rounds of $393k–$1.8M at Seed and $461k–$5.7M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Co-FundNI participates in.
When did Co-FundNI last invest?
The most recent investment recorded for Co-FundNI closed in Jul 2025. Shizune tracks 44 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
